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A total of 57 cases of West Nile virus infection (54 with 
neuroinvasive infection and three with fever) were 
identified in Romania between July and October 2010. 
The median age of the cases was 53.4 years, with 
the highest incidence in the age group 60–69 years. 
The case fatality rate was 8.8%. Cases were distrib-
uted in 19 districts in the southern, western, central 
and eastern parts of the country. Molecular investiga-
tion revealed lineage 2 West Nile virus, related to the 
Volgograd 2007 strain.
Introduction
On 28 August 2010, the National Reference Laboratory 
for Vector-borne Diseases in the Cantacuzino Institute 
in Romania reported to the National Centre for 
Surveillance and Control of Communicable Diseases 
(NCSCCD) 10 positive results for West Nile virus (WNV) 
in samples of patients distributed in nine different 
Romanian districts. Six of these 10 cases were male 
and four were female, with a median age of 56 years 
(range: 32–79 years). 
Romania recorded the first large outbreak of West 
Nile neuroinvasive disease (WNND) in Europe in 1996, 
with 393 confirmed cases. This was also the first such 
outbreak in urban settings. Cases were confined to 
Bucharest, its rural surroundings and 14 districts in 
the Danube Plain [1,2]. In response to this outbreak, in 
1997, the Ministry of Health set up a regional, hospital-
based surveillance system and sporadic cases were 
recorded every year in the districts neighbouring the 
Danube River [3]. In 2009, the surveillance system was 
extended at national level, following the confirmation 
of two cases of West Nile fever (WNF) in humans in 
the central part of Romania and the detection of WNV-
specific IgG antibodies among horses in many other 
areas of the country.
Within the routine WNV surveillance activities in 
Romania, the following case definition is used for a 
suspected case with WNV infection: a person over 15 
years of age who presents with fever and meningitis, 
encephalitis or meningoencephalitis between May and 
October and who reports a history of mosquito bites. 
Two sets of samples are collected for each suspected 
case: for patients with acute symptoms both cerebro-
spinal fluid (CSF) and serum are taken. For patients in 
convalescence phase, a second serum sample is taken 
14–21 days later. A probable or confirmed case of WNV 
infection is defined as a person who met the relevant 
clinical and the laboratory criteria for probable or con-
firmed cases described in the European Union case 
definition [4]. A suspected case is considered not to be 
a case if WNV-specific IgM was not detected in CSF and 
serum.
Data were obtained from infectious disease hospitals 
and reported using a standardised form containing 
information on symptoms, onset date and possible risk 
factors.
Following an outbreak of WNV infection in Greece in 
July to August 2010 [5], surveillance for WNND was 
enhanced in all districts in Romania from 12 August 
2010. All districts were asked to increase their vigi-
lance. In addition, the case definition for suspected 
cases used for routine surveillance was modified: a 
history of travel in the Danube Delta and/or in Greece 
was added.
Outbreak description
On 30 August 2010, after the 10 WNND cases had been 
reported on 28 August, the NCSCCD further reinforced 
the WNV surveillance activities in humans at national 
level and the case definition was modified once more: 
all persons aged over 15 years presenting with fever 
and meningitis or encephalitis or meningoencephalitis 
and clear CSF were considered suspected cases and 
were tested for WNV-specific antibodies. 
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After a cluster of five cases was recorded on 28 August 
2010 in a newly affected area in Central Transylvania 
(Alba district – Blaj city, Mures and Sibiu districts), 
active perifocal surveillance was set up locally for WNF 
cases as part of the enhanced surveillance: epidemi-
ologists were involved in retroactively identifying per-
sons who presented to general practitioners with fever 
and rash during August 2010. Samples from these 
patients were tested for the presence of WNV. 
The WNV surveillance season starts every year from 
early May and ends on 30 October. In 2010, the surveil-
lance season was exceptionally extended by two weeks 
in two places that were most affected by the outbreak 
(Bucharest city and Constanta district). From 10 May to 
15 November 2010, a total of 170 suspected cases with 
WNV infection were reported in Romania. Of these, 52 
were confirmed cases (49 with WNND and three with 
WNF), five were probable cases and 113 were negative 
for WNV. 
The first confirmed WNND case had symptom onset on 
4 July 2010 and the last on 11 October 2010. The dis-
tribution of the probable and confirmed cases of WNV 
infection by date of symptom onset is presented in 
Figure 1. 
The first case was diagnosed retroactively, during 
the investigation of a cluster of unexpected deaths 
in Constanta district, thought to be caused by hyper-
thermia due to high temperatures (39 °C) in early 
July 2010. For the rest of the cases, most (n=28) had 
symptom onset during the second half of August, 19 in 
September and only three cases had symptom onset in 
October (Figure 1). 
Among the 57 cases, the sex ratio (male:female) was 
1.7:1 (36 male:21 female). The median age was 53.4 
years (age range: 12–81 years). The highest number of 
cases (n=15) belonged to the age group 60–69 years 
(Figure 2).
The incidence per age group ranged from 0.1 to 0.8 per 
100,000 population, with the highest values being for 
the age groups 60–69 years (0.8 per 100,000 popula-
tion) and 70 years and above (0.5 per 100,000 popula-
tion). The lowest incidence was in the age groups under 
20 years and 20–29 years (0.1 per 100,000 population).
All confirmed and probable cases were hospitalised 
with WNV infection (31 with meningitis, 19 with menin-
goencephalitis and four with encephalitis). Three had 
non-neuroinvasive symptoms: two had fever and mac-
ulopapular exanthema and one had prolonged febrile 
syndrome. Among the severe cases, eight entered 
into a coma. Clinical symptoms included: fever (n=53), 
headache (n=50), stiff neck (n=42), shivering (n=26), 
confusion (n=21) vomiting (n=22), myalgia (n=25), 
disorientation (n=17), photophobia (n=12), Kernig sign 
(n=14), Brudzinski sign (n=8), memory loss (n=3), mac-
ulopapular exanthema (n=2).
Five deaths were recorded among the 57 identified 
cases, giving a case fatality rate of 8.8%. All deceased 
patients were aged over 65 years, and had underlying 
conditions (hypertension, diabetes). 
Of the 57 cases, 30 lived in urban settings and 27 in 
rural areas, giving an urban: rural ratio of 1.1:1.
Most cases (n=35) were recorded in the southern part 
of the country, an area known to be endemic for WNV 
from previous years. However, WNV infections were 
reported in humans in previously unaffected areas, 
such as districts in central Transylvania, and in the 
Moldavian Plateau (Figure 3). 
Figure 1
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a Increased vigilance and amendment of case definition.
b Reinforced surveillance activities and second amendment of the case definition.
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Laboratory investigation 
Serum and CSF samples were tested for the presence of 
IgM and IgG antibodies specific for WNV, using a com-
mercial enzyme-linked immunosorbent assay (ELISA) 
kits (Focus Technologies, USA). A total of 45 WNV neu-
roinvasive cases were confirmed by IgM-capture ELISA, 
based on the presence of WNV-specific IgM antibodies 
in CSF.
In nine cases with neurological clinical picture, CSF 
samples were either not available or were negative 
or borderline positive for WNV-specific IgM by ELISA. 
Serum samples from these cases were tested also by 
seroneutralisation assay using a lineage 1 WNV strain 
from Israel: four additional neuroinvasive cases were 
confirmed by the presence of WNV neutralising anti-
bodies in serum, while in the other five cases, the 
seroneutralisation assay was negative. In the three 
cases with non-neuroinvasive WNV infection, the infec-
tion was confirmed by the presence of WNV neutralis-
ing antibodies in serum.
Cases from Transylvania were also tested for the pres-
ence of tick-borne encephalitis virus-specific antibod-
ies because this virus had previously been found to be 
circulating in this area.
Serum and CSF samples were collected within five days 
from symptom onset from 16 of the 49 confirmed neu-
roinvasive cases; tissue samples were collected from 
one fatal case at the autopsy. Reverse transcription 
(RT) and real-time polymerase chain reaction (PCR) 
was used to detect the WNV genome in these samples. 
Figure 2
 Incidence rate of cases of West Nile Virus infection 


































































One dot represents one case.
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The target sequence was a conserved region of the 3´ 
non-coding region of WNV (Vázquez et al., unpublished 
data). In addition, partial sequence of the flavivirus 
NS5 gene was obtained following a generic RT-nested-
PCR to detect flaviviruses [6]. New degenerate internal 
primers were designed for sequencing. Virus culture 
was performed for the same cases using Vero and 
C6-36 cells, and gave negative results after three blind 
passages.
Molecular investigation detected the WNV genome in 
the brain tissue of the fatal case, and in the serum and/
or CSF of four of the 16 cases tested. Partial sequenc-
ing of the NS5 gene was performed for only one posi-
tive (approximately 1,200 genome equivalents/ml)) 
serum sample: analysis of 780 nucleotides of the NS5 
gene demonstrated that the virus was a WNV lineage 
2 strain, with 99.3% sequence identity to the virus cir-
culating in Volgograd in 2007 ( GenBank: FJ425721.1).
Public health measures
Surveillance has been gradually increased following 
reports of the outbreak of WNV infection in Greece 
and the detection of the first cases in Romania. The 
Ministry of Health and the regional public health 
authorities informed the local authorities about rec-
ommended measures for mosquito control and com-
municated data on the evolution of the outbreak to the 
general population on a weekly basis. The population 
was also informed about measures to reduce exposure 
to mosquitoes and to prevent mosquito bites. 
The Ministry of Health informed the National Institute 
of Haematology on a daily basis about the situation 
of the confirmed human cases of WNV infection and 
about the places where they have been identified. The 
National Institute of Haematology deferred donations 
from blood donors in rural areas until 1 December 2010. 
Initially, donations from affected urban areas were also 
deferred, but at a later stage, in order to maintain a 
sufficient blood supply, only donors from these areas 
presenting with a history of fever were excluded. In 
addition, those who donated blood were required to 
report to the Blood Donation Centre any symptoms of 
fever in the 15 days after giving blood. Donated blood 
was stored and not used before the five-day period 
had elapsed. Donors who had spent at least one night 
in areas with human cases of WNV infection were 
excluded from donation for a period of 28 days after 
having left the affected area.
Veterinary doctors were informed about the occur-
rence of WNV infection in humans and were requested 
to provide information on WNV infection in animals. 
According to the information received from the national 
veterinary authority, no dead birds infected with WNV 
and no cases of encephalomyelitis or recent WNV infec-
tion in horses have been recorded during the outbreak 
in humans. Seroprevalence studies found WNV-specific 
antibodies in poultry from two districts in the eastern 
and western parts of the country. WNV-specific IgG 
antibodies were detected in horses from 22 districts 
across the country, including nine districts in which 
human cases of WNV infection occurred in 2010.
Discussion
With 52 confirmed cases of WNV infection widely dis-
tributed in the country, the 2010 transmission season 
was associated with the most important WNV infection 
outbreak since 1997, when the WNV surveillance sys-
tem was implemented in Romania. 
Weather conditions (rainfalls, high temperatures) in 
2010 were favourable to the increase of mosquito pop-
ulations. Culex pipiens had already been identified as 
the vector of WNV in the 1996 outbreak [7]. In late sum-
mer, at least in urban areas, Cx. pipiens is the main 
mosquito biting humans, and we may assume that in 
this type of environment, this species was the WNV 
vector in 2010 also.
A specific feature of this outbreak was its extended 
area in the country: cases were distributed in 19 dis-
tricts, with some concentration of cases in the south-
eastern district of Constanta and in urban areas such 
as Blaj (western part) and Bucharest. Although most 
cases occurred in the already known endemic area in 
the south (in the Danube lowland and Delta neighbour-
ing counties), in the 2010 transmission season, cases 
were also recorded in previously unaffected areas, 
from the valleys of other major rivers, known to be bird 
migration pathways. 
Partial sequencing of the NS5 gene from a WNV-
positive serum of a Bucharest resident revealed a virus 
strain belonging to the genetic lineage 2, highly simi-
lar (99.3%) to the Volgograd strain involved in the 2007 
WNV outbreak in the Volga Delta area [8]. It is unsure 
whether the same WNV strain was involved in the out-
break beyond the Carpathian Mountains in Transylvania 
in 2010. Lineage 2 WNV strains were previously thought 
to be of low virulence. Nevertheless recent studies in 
South Africa suggest that lineage 2 WNV strains are a 
cause of neurological disease in horses and humans 
[9]. The WNV strain circulating in Romania from the 
1996 epidemic belonged to the genetic lineage 1 [7] 
and was associated with a case fatality rate of 4.3% 
(an 8.8% rate was recorded in 2010) [1]. In conclusion, 
a change in the epidemiological profile of WNV infec-
tion was recorded in 2010 in Romania, with emergence 
of cases in previously unaffected areas in western and 
eastern parts of the country, and the emergence of a 
neuroinvasive lineage 2 WNV strain.
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